19 recruiting. 19 Phase 3.
By phase and status
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Trials (filtered) newest first · largest first
All 19 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | 63 | 2026-09-15 | 2026-10-14 |
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 620 | 2026-08-03 | 2026-08-31 |
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Gamunex-C, 10% Injectable Solution - Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Recruiting | 49 | 2026-05-11 | 2026-10-01 |
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Surovatamig - Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | Phase 3 | Recruiting | 420 | 2026-05-05 | 2026-10-06 |
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Zanubrutinib, Sonrotoclax, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Recruiting | 466 | 2026-04-30 | 2026-10-02 |
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | 306 | 2026-04-23 | 2026-08-11 |
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Sonrotoclax, Zanubrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 500 | 2026-01-22 | 2026-09-28 |
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 250 | 2025-09-08 | 2026-06-03 |
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Tacabrutideg, Pirtobrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 500 | 2025-09-04 | 2026-09-28 |
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Sonrotoclax, Obinutuzumab, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 630 | 2025-06-11 | 2026-10-23 |
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 250 | 2025-04-10 | 2026-09-28 |
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Venetoclax, Acalabrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 170 | 2024-08-05 | 2026-04-09 |
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
American Ginseng, Placebo Administration, Questionnaire Administration - Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 222 | 2024-08-01 | 2026-10-20 |
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nemtabrutinib, Ibrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 1200 | 2023-12-13 | 2026-10-13 |
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | 735 | 2023-08-08 | 2026-10-15 |
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | 386 | 2022-12-26 | 2026-09-30 |
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic | Phase 3 | Recruiting | 737 | 2022-07-22 | 2026-08-17 |
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Obinutuzumab, Venetoclax, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 202 | 2022-04-19 | 2026-08-20 |
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 247 | 2021-03-02 | 2026-10-26 |
Narrower conditions
Leukemia, Lymphocytic, Chronic, B-Cell (18) · Lymphoma, Non-Hodgkin (4) · Multiple Myeloma (3) · Agammaglobulinemia (2) · Lymphoma, B-Cell (2) · Bacterial Infections (1) · Burkitt Lymphoma (1) · Chromosome 17 deletion (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphoma (1)
Broader conditions
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Chronic Disease (18) · Disease Attributes (18) · Hematologic Diseases (18) · Leukemia (18) · Leukemia, Lymphoid (18) · Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18)
Interventions
venetoclax (7) · Rituximab (4) · acalabrutinib (4) · obinutuzumab (4) · pirtobrutinib (4) · ARQ531 (2) · Bendamustine Hydrochloride (2) · Hizentra (2) · gamma-Globulins (2) · ibrutinib (2) · idelalisib (2) · zanubrutinib (2) · Asian ginseng (1) · Biopsy (1) · Fluid Therapy (1)
Sponsors
BeOne Medicines (4) · Merck Sharp & Dohme LLC (2) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · AstraZeneca (1) · CSL Behring (1) · Dizal Pharmaceuticals (1) · German CLL Study Group (1) · Grifols Biologicals, LLC (1) · Grifols Therapeutics LLC (1) · Loxo Oncology, Inc. (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Newave Pharmaceutical Inc (1) · Nurix Therapeutics, Inc. (1)
Countries
United States (17) · United Kingdom (10) · Australia (9) · Canada (9) · Germany (9) · Poland (8) · Spain (8) · Brazil (7) · France (7) · Italy (7) · Belgium (6) · China (6) · Czechia (6) · New Zealand (6) · Argentina (5)
Top investigators
Barbara Eichhorst, MD, Prof. (1) · Daniel S. Childs, MD (1) · Deborah M Stephens (1) · Jennifer R Brown, MD (1)
Results publications
PMID 41353787, PMID 41749915
NIH funding
2025 (3), 2023 (2), U10CA180888 (1)